Chl.Cm
CHL.CM operates in the healthcare sector, providing pharmaceutical products and services, and generates revenue primarily through the sale of its pharmaceutical offerings.
Business. CHL.CM operates in the healthcare sector, providing pharmaceutical products and services, and generates revenue primarily through the sale of its pharmaceutical offerings.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
CHL.CM operates in the healthcare sector, providing pharmaceutical products and services, and generates revenue primarily through the sale of its pharmaceutical offerings.
CHL.CM maintains a conservative capital structure with a debt-to-equity ratio of 0.22, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.32, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, which could signal potential liquidity constraints.
In terms of profitability, CHL.CM reports a return on equity (ROE) of 5.87% and a return on assets (ROA) of 3.61%. These figures are below the industry median for ROE and ROA, indicating that the company is generating returns that are less efficient compared to its peers. The company's operating income margin is 11.88%, which is also below the industry median, suggesting that it is less efficient in converting revenue into operating profit.
CHL.CM's revenue is primarily concentrated in its pharmaceutical segment, with no significant geographic diversification disclosed. The company's exposure to a single segment increases its vulnerability to market fluctuations in the pharmaceutical industry. There is no information provided on geographic revenue distribution, which limits the understanding of potential regional risks.
The company's growth trajectory is modest, with no significant revenue growth reported in the latest financial period. The outlook for the current fiscal year does not indicate a substantial increase in revenue, and the next fiscal year is expected to follow a similar trend. The company's capital expenditure is negative, indicating a reduction in investment in long-term assets, which could affect its future growth potential.
CHL.CM faces a medium level of risk, primarily due to its liquidity position. The company's net cash is negative after subtracting total debt, which could lead to liquidity constraints. The dilution potential is low, and there are no significant adjustments applied to the valuation metrics. The risk assessment does not indicate any major regulatory or operational risks that could significantly impact the company's performance.
There are no recent events or filings disclosed that would significantly impact CHL.CM's operations or financial position. The company's financial statements do not mention any recent strategic initiatives, mergers, or acquisitions that could alter its business model or market position.
- CHL.CM has a conservative capital structure with a low debt-to-equity ratio of 0.22.
- The company's profitability metrics, including ROE and ROA, are below the industry median.
- CHL.CM's revenue is concentrated in its pharmaceutical segment, increasing its vulnerability to market fluctuations.
- The company's growth trajectory is modest, with no significant revenue growth reported in the latest financial period.
- CHL.CM faces a medium level of liquidity risk due to its negative net cash position after subtracting total debt.
- **margin_outlook_rationale**: The company's operating income margin is below the industry median, indicating potential inefficiencies in converting revenue into profit.
- **rd_outlook_rationale**: There is no specific information provided on the company's research and development activities or their impact on future growth.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- CHL.CM Market data — financials · 2026-05-27